Pharma BD Deal Intelligence
CFO Adam Derbyshire: 'We believe peak-year sales for Solesta could exceed $500 million. We expect the transaction to be modestly accretive in 2012 and highly…
Salix CEO Carolyn Logan said peak-year sales for Solesta could exceed $500M and the deal would be modestly accretive in 2012 and highly accretive thereafter.
Definitive proxy/8-K filing confirming all-cash $300M acquisition of Oceana Therapeutics closed December 20, 2011, expanding Salix's portfolio with Solesta and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Salix acquired Oceana Therapeutics in an all-cash $300M deal to gain Solesta (FDA-approved May 2011 for fecal incontinence) and Deflux (pediatric VUR). Closed December 20, 2011. Solesta peak-sales potential cited at >$500M.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Salix Pharmaceuticals / Oceana Therapeutics, Inc. (this deal) | 2011 | $300M | 29 |
| Salix Pharmaceuticals / Santarus Inc. | 2013 | $2.6B | 29 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
← Browse all deals · How we score deals
More: 2011 deals · Gastroenterology deals